Synthesis and Quantitative Structure-Activity Relationships of Selective BCRP Inhibitors

ChemMedChem

Volumn 8, Issue 1, 2013, Pages 125-135

  Marighetti, Federico ^a   Steggemann, Kerstin ^a   Hanl, Markus ^a   Wiese, Michael ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

ABC transporter; Antitumor agents; BCRP; Drug design; Inhibitors; QSAR

Indexed keywords

2 (3 AMINOBENZAMIDO) N [4 (2 HYDROXYETHYL)PHENYL]BENZAMIDE; 2 (3 CHLOROBENZAMIDO) N [4 (2 HYDROXYETHYL)PHENYL]BENZAMIDE; 2 (4 AMINOBENZAMIDO) N [4 (2 HYDROXYETHYL)PHENYL]BENZAMIDE; 2 (4 CHLOROBENZAMIDO) N [4 (2 HYDROXYETHYL)PHENYL]BENZAMIDE; 2 (4 CYANOBENZAMIDO) N [4 (2 HYDROXYETHYL)PHENYL]BENZAMIDE; 2 (4 HYDROXYBENZAMIDO) N [4 (2 HYDROXYETHYL)PHENYL]BENZAMIDE; 2 (4 TERT BUTYLBENZAMIDO) N [4 (2 HYDROXYETHYL)PHENYL]BENZAMIDE; 2 (CYCLOHEXANCARBOXAMIDO) N [4 (2 HYDROXYETHYL)PHENYL]BENZAMIDE; 2 ACETAMIDO N [4 (2 HYDROXYETHYL)PHENYL]BENZAMIDE; 4 [2 [4 (2 HYDROXYETHYL)PHENYLCARBAMOYL]PHENYLCARBAMOYL]PHENYL ACETATE; 4 CHLORO N [4 (2 HYDROXYETHYL)PHENYL] 2 (4 NITROBENZAMIDO)BENZAMIDE; 5 CHLORO N [4 (2 HYDROXYETHYL)PHENYL] 2 (4 NITROBENZAMIDO)BENZAMIDE; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; FIRTECAN; MITOXANTRONE; N [2 [4 (2 HYDROXYETHYL)PHENYLCARBAMOYL]PHENYL] 3,4 DIMETHOXYBENZAMIDE; N [4 (2 HYDROXYETHYL)PHENYL] 2 (3 NITROBENZAMIDO)BENZAMIDE; N [4 (2 HYDROXYETHYL)PHENYL] 2 (4 ISOPROPOXYBENZAMIDO)BENZAMIDE; N [4 (2 HYDROXYETHYL)PHENYL] 2 (4 METHYLBENZAMIDO)BENZAMIDE; N [4 (2 HYDROXYETHYL)PHENYL] 2 (4 NITROBENZAMIDO)BENZAMIDE; N [4 (2 HYDROXYETHYL)PHENYL] 2 [4 (TRIFLUOROMETHYL)BENZAMIDO]BENZAMIDE; N [4 (2 HYDROXYETHYL)PHENYL] 3 (4 NITROBENZAMIDO)BENZAMIDE; N [4 (2 HYDROXYETHYL)PHENYL] 4 (4 NITROBENZAMIDO)BENZAMIDE; N [4 (2 HYDROXYETHYL)PHENYL] 4 METHOXY 2 (4 NITROBENZAMIDO)BENZAMIDE; N [4 (2 HYDROXYETHYL)PHENYL] 4 METHYL 2 (4 NITROBENZAMIDO)BENZAMIDE; N [4 (2 HYDROXYETHYL)PHENYL] 4,5 DIMETHOXY 2 (4 NITROBENZAMIDO)BENZAMIDE; N [4 (2 HYDROXYETHYL)PHENYL] 5 METHOXY 2 (4 NITROBENZAMIDO)BENZAMIDE; N [4 (2 HYDROXYETHYL)PHENYL] 5 METHYL 2 (4 NITROBENZAMIDO)BENZAMIDE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER CELL; CELL VIABILITY; CYTOTOXICITY; DRUG ACTIVITY; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROGEN BOND; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MITOXANTRONE; NEOPLASM PROTEINS; P-GLYCOPROTEIN; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUINOLINES;

EID: 84871668993     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201200377     Document Type: Article

References (21)

1. G. D. Leonard, T. Fojo, S. E. Bates, Oncologist 2003, 8, 411-424.
2. K. Moitra, M. Dean, Biol. Chem. 2011, 392, 29-37.
3. R. Juliano, V. Ling, Biochim. Biophys. Acta Biomembr. 1976, 455, 152-162.
4. B. Sarkadi, L. Homolya, G. Szakács, A. Váradi, Physiol. Rev. 2006, 86, 1179-1236.
5. J. Xu, Y. Liu, Y. Yang, S. E. Bates, J. T. Zhang, J. Biol. Chem. 2004, 279, 19781-19789.
6. F. Staud, P. Pavek, Int. J. Biochem. Cell Biol. 2005, 37, 720-725.
7. I. L. K. Wong, K. F. Chan, K. H. Tsang, C. Y. Lam, Y. Zhao, T. H. Chan, L. M. C. Chow, J. Med. Chem. 2009, 52, 5311-5322.
8. D. D. Mruk, L. Su, C. Y. Cheng, Trends Pharmacol. Sci. 2011, 32, 99-106.
9. S. Velamakanni, S. L. Wei, T. Janvilisri, H. W. vanVeen, J. Bioenerg. Biomembr. 2007, 39, 465-471.
10. C. Lemos, G. Jansen, G. J. Peters, Br. J. Cancer 2008, 98, 857-862.
11. E. R. P. OudeElferink, D. Meijer, F. Kuipers, P. Jansen, A. K. Groen, G. Groothuis, Biochim. Biophys. Acta Rev. Biomembr. 1995, 1241, 215.
12. R. W. Robey, Cancer Res. 2004, 64, 1242-1246.
13. W. Liu, M. R. Baer, M. J. Bowman, P. Pera, X. Zheng, J. Morgan, R. Pandey, A. R. Oseroff, Clin. Cancer Res. 2007, 13, 2463-2470.
14. A. Pick, H. Müller, M. Wiese, Bioorg. Med. Chem. 2008, 16, 8224-8236.
15. A. Azzariti, L. Porcelli, G. M. Simone, A. E. Quatrale, N. Colabufo, F. Berardi, R. Perrone, M. Zucchetti, M. D′Incalci, J. M. Xu, A. Paradiso, Cancer Chemother. Pharmacol. 2010, 65, 335-336.
16. A. Ahmed-Belkacem, A. Pozza, S. Macalou, J. M. Pèrez-Victoria, A. Boumendjel, A. DiPietro, Anticancer Drugs 2006, 17, 239-243.
17. A. Pick, W. Klinkhammer, M. Wiese, ChemMedChem 2010, 5, 1498-1505.
18. MOE 2010.10 (Molecular Operating Environment), Chemical Computing Group, 1010 Sherbrooke Street West, Suite 910, Montréal, QC, H3A2R7 (Canada).
19. H. Müller, M. Kassack, M. Wiese, J. Biol. Screen. 2004, 9, 506-515.
20. H. Müller, W. Klinkhammer, C. Globisch, M. U. Kassack, I. K. Pajeva, M. Wiese, Bioorg. Med. Chem. 2007, 15, 7470-7479.
21. W. Klinkhammer, H. Müller, C. Globisch, I. K. Pajeva, M. Wiese, Bioorg. Med. Chem. 2009, 17, 2524-2535.